FARICIMAB

N/A

Manufactured by Genentech, Inc.

11,141 FDA adverse event reports analyzed

Last updated: 2026-04-15

About FARICIMAB

FARICIMAB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Genentech, Inc.. The most commonly reported adverse reactions for FARICIMAB include OFF LABEL USE, NO ADVERSE EVENT, VISUAL IMPAIRMENT, DRUG INEFFECTIVE, DEATH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FARICIMAB.

Top Adverse Reactions

OFF LABEL USE2,275 reports
NO ADVERSE EVENT1,900 reports
VISUAL IMPAIRMENT479 reports
DRUG INEFFECTIVE325 reports
DEATH309 reports
UVEITIS309 reports
EYE INFLAMMATION306 reports
RETINAL THICKENING299 reports
ENDOPHTHALMITIS237 reports
BLINDNESS224 reports
VITRITIS218 reports
VITREOUS FLOATERS214 reports
VISION BLURRED201 reports
IRIDOCYCLITIS193 reports
OPTICAL COHERENCE TOMOGRAPHY ABNORMAL175 reports
VISUAL ACUITY REDUCED171 reports
EYE PAIN154 reports
INTRAOCULAR PRESSURE INCREASED138 reports
RETINAL HAEMORRHAGE129 reports
EYE DISORDER110 reports
INFLAMMATION89 reports
IRITIS86 reports
PAIN83 reports
CATARACT80 reports
EYE HAEMORRHAGE69 reports
HEADACHE69 reports
INTERCEPTED PRODUCT STORAGE ERROR66 reports
KERATIC PRECIPITATES62 reports
NEOVASCULAR AGE RELATED MACULAR DEGENERATION62 reports
VISUAL ACUITY TESTS ABNORMAL62 reports
BLINDNESS UNILATERAL59 reports
OCULAR HYPERAEMIA58 reports
ANTERIOR CHAMBER INFLAMMATION57 reports
CEREBROVASCULAR ACCIDENT56 reports
RETINAL VASCULITIS54 reports
RETINAL PIGMENT EPITHELIAL TEAR53 reports
LACRIMATION INCREASED50 reports
DIZZINESS49 reports
DRY EYE49 reports
RETINAL OCCLUSIVE VASCULITIS48 reports
EYE IRRITATION47 reports
VASCULITIS42 reports
FALL41 reports
SUSPECTED TRANSMISSION OF AN INFECTIOUS AGENT VIA PRODUCT39 reports
VITREOUS HAEMORRHAGE39 reports
HAEMORRHAGE36 reports
RETINAL VEIN OCCLUSION36 reports
GLAUCOMA35 reports
ILL DEFINED DISORDER35 reports
PHOTOPHOBIA35 reports
MALAISE33 reports
CHORIORETINITIS31 reports
INJECTION SITE PAIN31 reports
VITREOUS OPACITIES31 reports
DIABETIC RETINOPATHY30 reports
FOREIGN BODY SENSATION IN EYES30 reports
HYPOPYON30 reports
OCULAR HYPERTENSION30 reports
PRODUCT STORAGE ERROR29 reports
RETINAL ARTERY OCCLUSION29 reports
EYE SWELLING28 reports
RETINAL DETACHMENT28 reports
CORNEAL OEDEMA27 reports
OCULAR VASCULITIS27 reports
EYE INFECTION26 reports
HYPERTENSION26 reports
PNEUMONIA26 reports
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS26 reports
FATIGUE25 reports
NON INFECTIOUS ENDOPHTHALMITIS25 reports
ANTERIOR CHAMBER CELL24 reports
MACULAR DEGENERATION24 reports
SUBRETINAL FLUID24 reports
CEREBRAL INFARCTION23 reports
RETINAL OEDEMA21 reports
OEDEMA20 reports
PRODUCT COMPLAINT20 reports
COVID 1919 reports
DETACHMENT OF RETINAL PIGMENT EPITHELIUM19 reports
INTRA OCULAR INJECTION COMPLICATION19 reports
MYOCARDIAL INFARCTION19 reports
NAUSEA19 reports
PHOTOPSIA19 reports
RASH19 reports
BLINDNESS TRANSIENT18 reports
GAIT DISTURBANCE18 reports
METAMORPHOPSIA18 reports
OCULAR DISCOMFORT18 reports
BLOOD PRESSURE INCREASED17 reports
CONDITION AGGRAVATED17 reports
DRUG HYPERSENSITIVITY17 reports
DYSPNOEA17 reports
EYE DISCHARGE17 reports
IDIOPATHIC ORBITAL INFLAMMATION17 reports
NEOPLASM MALIGNANT17 reports
VERTIGO17 reports
VITREAL CELLS17 reports
CONJUNCTIVAL HAEMORRHAGE16 reports
DISCOMFORT16 reports
ANXIETY15 reports

Report Outcomes

Out of 6,489 classified reports for FARICIMAB:

Serious 40.9%Non-Serious 59.1%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female2,662 (53.7%)
Male2,290 (46.2%)
Unknown1 (0.0%)

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with FARICIMAB?

This profile reflects 11,141 FDA FAERS reports that mention FARICIMAB. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for FARICIMAB?

Frequently reported terms in FAERS include OFF LABEL USE, NO ADVERSE EVENT, VISUAL IMPAIRMENT, DRUG INEFFECTIVE, DEATH, UVEITIS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures FARICIMAB?

Labeling and FAERS entries often list Genentech, Inc. in connection with FARICIMAB. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.